10:46 AM EST, 03/05/2024 (MT Newswires) -- Apogee Therapeutics ( APGE ) said Tuesday the phase 1 trial of APG777 to treat moderate to severe atopic dermatitis and other inflammatory conditions has exceeded objectives.

The company said pharmacokinetic data indicated a half-life of about 75 days across various doses tested while pharmacodynamic data showed significant suppression of crucial atopic dermatitis biomarkers, lasting for nearly three months.

Apogee also said APG777 was well-tolerated with a favorable safety profile.

The company said it plans to start a randomized, placebo-controlled phase 2 clinical trial for moderate to severe atopic dermatitis in the first half of 2024, with proof of concept data expected in the second half of 2025.

Shares of Apogee were up more than 39% in recent Tuesday trading.

Price: 58.16, Change: +16.42, Percent Change: +39.34